Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD5 | P21918 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4644536 | 0.84 | HTR2A (0.37) | TRPA1 | |
| Methyl Alcohol SCHEMBL28424110 | 0.81 | HTR2A (0.35) | TRPA1 | |
| SCHEMBL27498922 | 0.81 | HTR2A (0.35) | TRPA1 | |
| Methane SCHEMBL29046923 | 0.81 | HTR2A (0.35) | TRPA1 | |
| SCHEMBL597727 | 0.77 | ADRA2A (0.43) | ADRA2ATSHRSIGMAR1NOTUMHTR2C | |
| SCHEMBL8162271 | 0.77 | ADRA2A (0.43) | ADRA2ATSHRSIGMAR1ATMHTR2C | |
| SCHEMBL4395730 | 0.75 | HTR2A (0.43) | HTR2CKDM1A | |
| SCHEMBL20404660 | 0.74 | KDM1A (0.42) | ADRA2ATSHRSIGMAR1NOTUMHTR2C | |
| SCHEMBL9418958 | 0.74 | TSHR (0.48) | ADRA2ATSHRSIGMAR1NOTUMHTR2C | |
| SCHEMBL14658768 | 0.74 | ATM (0.39) | ADRA2ATSHRSIGMAR1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772433-B2 | SARMS and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080057068-A1 | SARMS and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2008-03-06 | — | — | US | disclosed |
| CN-1057522-C | Naphthalene derivs. as prostaglandin I2 agonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-10-18 | — | — | CN | disclosed |
| CN-1147250-A | Naphthalene derivs. as prostaglandin I2 agonists | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-04-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080057068-A1 | SARMS and method of use thereof | SARM1, CKMT1A; CKMT1B, TNNI3 | ADRA2A 617/4885TSHR 2773/4885SIGMAR1 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.